NCT06239116View on ClinicalTrials.gov

A Study of RM-718 in Healthy Subjects and in Patients With HO

PHASE1RecruitingINTERVENTIONAL
Enrollment

120

Participants

Timeline

Start Date

March 5, 2024

Primary Completion Date

May 4, 2026

Study Completion Date

May 4, 2026

Conditions
Hypothalamic Obesity
Interventions
DRUG

Part A: RM-718 or placebo (matched to specific RM-718 dose cohort)

Single ascending dose of RM-718 or placebo (matched to specific RM-718 Part A dose cohort)

DRUG

Part B: RM-718 or placebo (matched to specific RM-718 dose cohort)

Multiple ascending doses of RM-718 or placebo (matched to specific RM-718 Part B dose cohorts)

DRUG

Part C: RM-718

Multiple ascending doses of RM-718 (specific to Part C single cohort)

Trial Locations (7)

35233

RECRUITING

UAB Pediatric Endocrinology, Birmingham

37232

RECRUITING

Vanderbilt University Medical Center, Nashville

60611

RECRUITING

Ann and Robert H. Lurie Children's Hospital of Chicago, Chicago

78217

COMPLETED

Worldwide Clinical Trials, San Antonio

84112

RECRUITING

University of Utah Pediatric Endocrine Clinic, Salt Lake City

021115

NOT_YET_RECRUITING

Boston Children's Hospital, Boston

02115

RECRUITING

Brigham and Women's Hospital, Boston

All Listed Sponsors
lead

Rhythm Pharmaceuticals, Inc.

INDUSTRY